(R)-N-(1-(3-(4-cyanophenyl)quinolin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide | 1010857-98-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (R)-N-(1-(3-(4-cyanophenyl)quinolin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide
• 英文别名: N-[(1R)-1-[3-(4-cyanophenyl)quinolin-2-yl]ethyl]-N-(2-ethylsulfonylethyl)-2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide
• CAS: 1010857-98-3
• 化学式: C₃₁H₂₇F₄N₃O₃S
• 分子量: 597.633
• InChiKey: XWZAPHVEMQANSG-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  99.5
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(3-(4-iodophenyl)quinolin-2-yl)ethyl)acetamide 、 氰化钠 在 四(三苯基膦)钯 copper(l) iodide 作用下， 以 乙腈 为溶剂， 生成 、 (R)-N-(1-(3-(4-cyanophenyl)quinolin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide
  参考文献：
  名称：

  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

  摘要：

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.060

文献信息

• Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists
  作者：An-Rong Li、Michael G. Johnson、Jiwen Liu、Xiaoqi Chen、Xiaohui Du、Jeffrey T. Mihalic、Jeffrey Deignan、Darin J. Gustin、Jason Duquette、Zice Fu、Liusheng Zhu、Andrew P. Marcus、Phillipe Bergeron、Lawrence R. McGee、Jay Danao、Bryan Lemon、Teresa Carabeo、Timothy Sullivan、Ji Ma、Liang Tang、George Tonn、Tassie L. Collins、Julio C. Medina

  DOI：10.1016/j.bmcl.2007.11.060

  日期：2008.1

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.